Combination phenylbutyrate/gemcitabine therapy effectively inhibits in vitro and in vivo growth of NSCLC by intrinsic apoptotic pathways

BACKGROUND: Standard chemotherapy protocols in NSCLC are of limited clinical benefit. Histone deacetylase (HDAC) inhibitors represent a new strategy in human cancer therapy. In this study the combination of the HDAC inhibitor phenylbutyrate (PB) and the nucleoside analogue gemcitabine (GEM) was eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Schniewind, Bodo, Heintz, Kirsten, Kurdow, Roland, Ammerpohl, Ole, Trauzold, Anna, Emme, Doris, Dohrmann, Peter, Kalthoff, Holger
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1665446/
https://www.ncbi.nlm.nih.gov/pubmed/17123441
http://dx.doi.org/10.1186/1477-3163-5-25

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1665446/
https://www.ncbi.nlm.nih.gov/pubmed/17123441
http://dx.doi.org/10.1186/1477-3163-5-25

Ejemplares similares